Integragen (ALINT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Integragen (ALINT) has a cash flow conversion efficiency ratio of -1.910x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-645.51K ≈ $-754.67K USD) by net assets (€338.04K ≈ $395.20K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Integragen - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Integragen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Integragen (ALINT) financial obligations for a breakdown of total debt and financial obligations.
Integragen Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integragen ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tres Or Resources Ltd
V:TRS
|
-0.004x |
|
The Real Good Food Company, Inc.
NYSE:RGFC
|
N/A |
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
-0.007x |
|
Lucibel
PA:ALUCI
|
6.802x |
|
Tower Investments SA
WAR:TOW
|
-0.116x |
|
Sarawak Cable Bhd
KLSE:5170
|
0.002x |
|
Savoreat Ltd
TA:SVRT
|
-0.762x |
|
AfriTin Mining Ltd
LSE:ATM
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Integragen (2012–2022)
The table below shows the annual cash flow conversion efficiency of Integragen from 2012 to 2022. For the full company profile with market capitalisation and key ratios, see Integragen market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €2.20 Million ≈ $2.57 Million |
€403.11K ≈ $471.28K |
0.183x | -2.75% |
| 2021-12-31 | €2.19 Million ≈ $2.56 Million |
€411.78K ≈ $481.41K |
0.188x | -9.62% |
| 2020-12-31 | €2.17 Million ≈ $2.54 Million |
€452.69K ≈ $529.24K |
0.208x | +104.19% |
| 2019-12-31 | €2.51 Million ≈ $2.93 Million |
€256.10K ≈ $299.41K |
0.102x | +109.82% |
| 2018-12-31 | €2.79 Million ≈ $3.27 Million |
€135.90K ≈ $158.88K |
0.049x | +55.07% |
| 2017-12-31 | €3.93 Million ≈ $4.60 Million |
€123.30K ≈ $144.15K |
0.031x | -61.91% |
| 2016-12-31 | €1.28 Million ≈ $1.50 Million |
€105.62K ≈ $123.49K |
0.082x | +102.29% |
| 2013-12-31 | €691.87K ≈ $808.87K |
€-2.49 Million ≈ $-2.91 Million |
-3.592x | -693.04% |
| 2012-12-31 | €3.24 Million ≈ $3.78 Million |
€-1.47 Million ≈ $-1.71 Million |
-0.453x | -- |
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more